Lorenzo Nibid
A5058075337- Cancer Immunotherapy and Biomarkers
- Diabetes Treatment and Management
- Pancreatic and Hepatic Oncology Research
- Neutropenia and Cancer Infections
- Hyperglycemia and glycemic control in critically ill and hospitalized patients
- Metabolism, Diabetes, and Cancer
- Cancer Genomics and Diagnostics
- Colorectal Cancer Treatments and Studies
- Immune cells in cancer
- Inflammatory Biomarkers in Disease Prognosis
- Economic and Financial Impacts of Cancer
- Radiomics and Machine Learning in Medical Imaging
- Lung Cancer Diagnosis and Treatment
- Diabetes and associated disorders
- Gastric Cancer Management and Outcomes
- Renal Transplantation Outcomes and Treatments
- Chronic Lymphocytic Leukemia Research
- Ferroptosis and cancer prognosis
- AI in cancer detection
- Medication Adherence and Compliance
- Advanced Breast Cancer Therapies
- Sarcoma Diagnosis and Treatment
- Molecular Biology Techniques and Applications
- PARP inhibition in cancer therapy
- Oral and Maxillofacial Pathology
Università Campus Bio-Medico
2021-2025
Campus Bio Medico University Hospital
2022-2025
Abstract Purpose: No evidence exists as to whether type 2 diabetes mellitus (T2DM) impairs clinical outcome from immune checkpoint inhibitors (ICI) in patients with solid tumors. Experimental Design: In a large cohort of ICI recipients treated at 21 institutions June 2014 2020, we studied on glucose-lowering medications (GLM) for T2DM had shorter overall survival (OS) and progression-free (PFS). We used targeted transcriptomics subset explore differences the tumor microenvironment (TME) or...
The current cancer treatment practice collects multimodal data, such as radiology images, histopathology slides, genomics and clinical data. importance of these data sources taken individually has fostered the recent raise radiomics pathomics, i.e. extraction quantitative features from images routinely collected to predict outcomes or guide decisions using artificial intelligence algorithms. Nevertheless, how combine them into a single framework is still an open issue. In this work we...
Dedifferentiated liposarcoma (DDLPS) is one of the most common subtypes soft tissue sarcoma with a highly variable clinical behavior. Despite advanced molecular approaches are exploring genetic panorama DDLPS progression, to date driver genes aggressive behavior in have not been identified yet. Here, we used Nanostring nCounter approach study gene expression profile 60 selected involved cohort behavior, comparison indolent We five whose significantly and consistently altered compared DDLPS....
Background: Approximately 25.0% of metastatic prostate cancer patients harbour DNA damage repair mutations, including BRCA1 and BRCA2, which are actionable targets for poly(ADP-ribose) polymerase (PARP) inhibitors. Accurate detection BRCA1/2 mutations is critical guiding targeted therapies, but crucial pre-analytical factors, such as tissue storage duration fragmentation, drastically affect the reliability next-generation sequencing (NGS) using real-world diagnostic specimens. Methods: This...
Despite the advantages offered by personalized treatments, there is presently no way to predict response chemoradiotherapy in patients with non-small cell lung cancer (NSCLC). In this exploratory study, we investigated application of deep learning techniques histological tissue slides (deep pathomics), aim predicting therapy stage III NSCLC. We evaluated 35 digitalized (biopsies or surgical specimens) obtained from IIIA IIIB Patients were classified as responders (12/35, 34.7%)...
In advanced or metastatic settings, Comprehensive Genomic Profiling (CGP) allows the evaluation of thousands gene alterations with goal offering new opportunities for personalized treatment in solid tumors. This study evaluated CGP Success Rate a real-life cohort 184 patients enrolled prospective clinical trial. data were compared routine molecular testing strategy adopted in-house. Sample age, tumor area, and percentage nuclei recorded analysis. We found that 150/184 (81.5%) samples...
Importance Only a small fraction of patients with advanced non−small cell lung cancer (NSCLC) respond to immune checkpoint inhibitor (ICI) treatment. For optimal personalized NSCLC care, it is imperative identify who are most likely benefit from immunotherapy. Objective To develop supervised deep learning−based ICI response prediction method; evaluate its performance alongside other known predictive biomarkers; and assess association clinical outcomes in NSCLC. Design, Setting, Participants...
hERG1 potassium channels are widely expressed in human cancers of different origins, where they affect several key aspects cellular behaviour. The present study was designed to evaluate the expression and clinical relevance protein cancer tissues from patients suffering neuroendocrine tumours (NETs) ileal (iNETs) pancreatic (pNETs) origin, with available clinicopathological history follow-up. carried out by immunohistochemistry an anti-hERG1 monoclonal antibody. In a subset samples, antibody...
<p>Tumour micron-environment transcriptome analysis.</p>
Primary acinic cell carcinoma (ACC) of the lung is an extremely rare neoplasm that more often arises near to a right bronchus. It characterized by two populations clear and dark eosinophilic cells, arranged in glandular acinar pattern. Mitosis are tumor cells show small eccentric nuclei. Positive stain for PAS, PAS-D, cytokeratin, A1AT A1ACT reported, while TTF1, p40, synaptophysin, SMA, S100 substantially negative. DOG-1 positive was observed ACC salivary glands its negativity proposed...
Autologous hamstrings and patellar tendon have historically been considered the gold standard grafts for anterior cruciate ligament reconstruction (ACLR). In last decades, utilization of synthetic has re-emerged due to advantageous lack donor site morbidity more rapid return sport. The Ligament Augmentation Reconstruction System (LARS) demonstrated be a valid safe option ACLR in short term. However, recent studies pointed out notable frequency associated complications, including synovitis,...
Recent years have witnessed the rise of pathomics as a mean to describe histopathological images with quantitative biomarkers for predictive and prognostic ends, combining digital pathology, omic science artificial intelligence. This novel research branch is counterpart radiomics which pursues same aims extracting knowledge from radiological images. In this paper, we present design pathomic deep learning-based system predict treatment outcome in non-small cell lung cancer patients. We...
RNA-based next-generation sequencing (RNA-seq) represents the gold standard for detecting gene fusion in non-small cell lung cancer (NSCLC). Despite this, RNA instability makes management of tissue samples extremely complex, resulting a significant number test failures with missing data or need to switch other techniques. In present study, we analyzed pre-analytical variables 140 tumor from patients affected by NSCLC detect features that increase chances successful RNA-seq. We found success...
Trabectedin, approved for the treatment of soft tissue sarcoma (STS), interferes with cell division and genetic transcription processes. Due to its strong anti-tumor activity in only certain histotypes, several studies on trabectedin combinations are currently ongoing improve efficacy. In this study, we aimed investigate novel potential therapeutic strategies enhance effect using integrated silico, vitro, vivo approaches. For silico analysis, screened two public datasets, GSEA M5190 TCGA...
<p>Kaplan-Meier survival estimates according to the receipt of no diabetes medication, other medications/insulin therapy only, and metformin (either alone or in combinations). A) Overall Survival whole cohort; patients not receiving medications: 18.9 months (95%CI: 15.9-21.6; 684 events), on only: 19.3 11.6-22.9; 48 metformin: 12.3 9.8-15.9; 100 events). B) Progression Free 8.2 7.1-9.4; 872 10.7 6.7-11.6; 61 7.9 5.1-10.1; 124 events).</p>
<p>Kaplan-Meier survival estimates according to the receipt of other diabetes medications and insulin therapy. A) Overall Survival whole cohort; patients on oral antidiabetic drugs therapy: 17.5 months (95%CI: 12.8-20.9; 82 events), not receiving therapy 17.8 15.4 – 19.7; 750 events). B) Progression Free 8.2 6.2-11.4; 106 8.1 7.1 9.2; 951 events).</p>
<p>Kaplan-Meier survival estimates according to the receipt of metformin. A) Overall Survival whole cohort; patients on metformin: 12.4 months (95%CI: 10.5-16.3; 100 events), not receiving 19.0 16.4 – 21.1; 732 events). B) Progression Free 7.9 5.3-10.1; 124 8.3 7.3 9.5; 933 events).</p>